TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Control Bionics Ltd. ( (AU:CBL) ) is now available.
Control Bionics Limited has successfully raised $3.25 million through a private placement of 50 million new shares, priced at $0.065 each. This funding, anchored by Reitham Equity GmbH, will enhance the company’s working capital to accelerate its commercialization programs in assistive technology and emerging neurotechnology markets. The investment is expected to strengthen Control Bionics’ global footprint and support key initiatives in assistive communication, rehabilitation, and sports performance, ultimately improving the quality of life and performance for users worldwide.
The most recent analyst rating on (AU:CBL) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Control Bionics Ltd. stock, see the AU:CBL Stock Forecast page.
More about Control Bionics Ltd.
Control Bionics is a medical device company with over 20 years of experience in developing surface Electromyography (EMG) devices. Its core technology, NeuroNode, is a wireless wearable device that captures EMG output to enable speech and computer-controlled functions. The company is also commercializing the NeuroStrip, a miniaturized EMG device for new markets such as health diagnostics, sports performance, and rehabilitation. Control Bionics operates in North America, Australia, Singapore, and Japan.
Average Trading Volume: 1,062,519
Technical Sentiment Signal: Buy
Current Market Cap: A$24.04M
For a thorough assessment of CBL stock, go to TipRanks’ Stock Analysis page.